CClinicalTrials.gg
Sign In
CompletedNCT01826409Updated Aug 29, 2013

Hypoglycemic Effects of Fermented Red Ginseng in Subject With Impaired Fasting Glucose or Type 2 Diabetes

A Phase 2/3 interventional study of Fermented Red Ginseng and Placebo in Impaired Glucose or Type 2 Diabetes, sponsored by Chonbuk National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-08-29.

Sponsored by Chonbuk National University Hospital · Phase 2/3, Interventional, and Prevention

Phase
Phase 2/3
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Study summary

This study was conducted to investigate the effects of daily supplementation of fermented red ginseng (FRG) on glycemic status in subjects with impaired fasting glucose (IFG) or type 2 diabetes.

Read the detailed description

This study was a 4 weeks, randomized, double-blind, placebo-controlled trial. Forty-two subjects with IFG or type 2 diabetes were randomly allocated to 2 groups to consume placebo or FRG three times per day for 4 weeks. Fasting and postprandial glucose profiles during meal tolerance test were assessed before and after the intervention.

02

Conditions studied

  • Impaired Glucose or Type 2 Diabetes
03

In context

Diabetes Mellitus, Type 2

9,359 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,318 are open to participants now.

This study's enrollment of 42 is below the median of 80 across 7,525 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Chonbuk National University Hospital is the lead sponsor of 88 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 20-75 years with fasting glucose 100\~140 mg/dL at least two of the following

Exclusion criteria

Exclusion Criteria:

  • Lipid metabolic disorder
  • Acute or chronic inflammatory disease
  • Taking medication of corticosteroid within 4 weeks of the study
  • Cardiovascular disease (arrhythmia, heart failure, myocardial infarction or patient with pacemaker)
  • Allergic or hypersensitive to any of the ingredients in the test products
  • Participation in other clinical trials within 2 months
  • Abnormal hepatic liver function or renal disease (acute/chronic renal failure or nephrotic syndrome)
  • Taking medication of lipid phosphates within 3 months of the study etc,
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Fermented red ginseng

    Dietary Supplement: Fermented Red Ginseng

  • Placebo comparator
    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementFermented Red Ginseng

    Fermented red ginseng 2.7g/day for 4 weeks

  • Dietary supplementPlacebo

    Placebo 2.7g/day for 4 weeks

06

What researchers measure

Primary outcomes

  1. Glucose profiles during meal tolerance test

    Fasting and postprandial glucose profiles during meal tolerance test were assessed before(baseline) and after the intervention

    Time frame: 4 weeks

Secondary outcomes

  1. Change in lipid profiles

    Change in lipid profiles were assessed before(baseline) and after the intervention

    Time frame: 4 weeks

07

Study locations

1 site
  • Clincial Trial Center for Functional Foods
    Jeonju, Jeollabok-do 560-822, Korea, Republic of
08

References and documents

Publications

  • Oh MR, Park SH, Kim SY, Back HI, Kim MG, Jeon JY, Ha KC, Na WT, Cha YS, Park BH, Park TS, Chae SW. Postprandial glucose-lowering effects of fermented red ginseng in subjects with impaired fasting glucose or type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. BMC Complement Altern Med. 2014 Jul 11;14:237. doi: 10.1186/1472-6882-14-237. PubMed 25015735 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01826409
Lead sponsor
Chonbuk National University Hospital
Responsible party
Soo-Wan Chae (Principal Investigator, Clinical Trial Center for Functional Foods, Chonbuk National University Hospital) — Principal investigator
First posted
Apr 8, 2013
Start date
Mar 2008
Primary completion
Sep 2009
Last update
Aug 29, 2013

Study contacts

Tae Sun Park, MD., PhD
principal investigator · Chonbuk National University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Diabetes Mellitus, Type 2→

Other studies from this sponsor

Chonbuk National University Hospital

Start the discussion